The Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
Cancer Discov. 2022 Nov 2;12(11):2606-2625. doi: 10.1158/2159-8290.CD-21-1714.
It is currently accepted that cancer-associated fibroblasts (CAF) participate in T-cell exclusion from tumor nests. To unbiasedly test this, we used single-cell RNA sequencing coupled with multiplex imaging on a large cohort of lung tumors. We identified four main CAF populations, two of which are associated with T-cell exclusion: (i) MYH11+αSMA+ CAF, which are present in early-stage tumors and form a single cell layer lining cancer aggregates, and (ii) FAP+αSMA+ CAF, which appear in more advanced tumors and organize in patches within the stroma or in multiple layers around tumor nests. Both populations orchestrate a particular structural tissue organization through dense and aligned fiber deposition compared with T cell-permissive CAF. Yet they produce distinct matrix molecules, including collagen IV (MYH11+αSMA+ CAF) and collagen XI/XII (FAP+αSMA+ CAF). Hereby, we uncovered unique molecular programs of CAF driving T-cell marginalization, whose targeting should increase immunotherapy efficacy in patients bearing T cell-excluded tumors.
The cellular and molecular programs driving T-cell marginalization in solid tumors remain unclear. Here, we describe two CAF populations associated with T-cell exclusion in human lung tumors. We demonstrate the importance of pairing molecular and spatial analysis of the tumor microenvironment, a prerequisite to developing new strategies targeting T cell-excluding CAF. See related commentary by Sherman, p. 2501. This article is highlighted in the In This Issue feature, p. 2483.
目前人们普遍认为癌症相关成纤维细胞(CAF)参与了 T 细胞从肿瘤巢中的排除。为了公正地检验这一点,我们使用单细胞 RNA 测序并结合大量肺肿瘤的多重成像进行了研究。我们确定了四种主要的 CAF 群体,其中两种与 T 细胞排斥有关:(i)MYH11+αSMA+CAF,存在于早期肿瘤中,并形成单层排列在癌细胞团周围;(ii)FAP+αSMA+CAF,出现在更晚期的肿瘤中,并在基质中形成斑块或围绕肿瘤巢的多层排列。这两种群体都通过密集且排列整齐的纤维沉积来协调特定的结构组织,与允许 T 细胞进入的 CAF 相比。然而,它们产生不同的基质分子,包括胶原蛋白 IV(MYH11+αSMA+CAF)和胶原蛋白 XI/XII(FAP+αSMA+CAF)。由此,我们揭示了 CAF 驱动 T 细胞边缘化的独特分子程序,针对这些程序的靶向治疗应该会提高携带 T 细胞排斥肿瘤的患者的免疫治疗效果。
实体瘤中驱动 T 细胞边缘化的细胞和分子程序仍不清楚。在这里,我们描述了与人类肺肿瘤中 T 细胞排斥相关的两种 CAF 群体。我们证明了对肿瘤微环境进行分子和空间分析的重要性,这是开发针对排斥 T 细胞的 CAF 的新策略的前提。见 Sherman 的相关评论,第 2501 页。本文在本期特色栏目中重点介绍,第 2483 页。